# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0....
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:COCP) with a Buy and maintains $10 pr...
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trialBOTHELL, Wash., March 19, 2024 (GLOBE NE...
Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") provides an update on the clinical developm...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy and lowers the price ...
-8-K
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:COCP) with a Buy and maintains $12 pr...